The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms.

  • FaceDeer@kbin.social
    link
    fedilink
    arrow-up
    4
    ·
    1 year ago

    The results regarding amyloid plaques just keep going back and forth over time, I’m very curious how this will ultimately play out. I suppose even if the plaques are a symptom rather than the underlying cause it can still be helpful clearing them away.